Bluebird bio Inc

Bluebird bio — Conference Presentation (January 2021)

27 slides from Bluebird bio's conference presentation, Jan 11, 2021

  1. Slide 1: Recoding For The Future

    1 NASDAQ: BLUE Recoding For The Future January 2021 Company Presentation Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    2 These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar exp

  3. Slide 3: Our True North

    3 Our True North THE FACES THE STORIES WHY?

  4. Slide 4: A Decade of Advancing Programs Through the Clinic

    4 L e n ti G lo b in f o r T D T id e -ce l (b b 2 1 2 1 ) 4 for 4: A Decade of Advancing Programs Through the Clinic to Deliver Life- Changing Medicines to Patients Robust Platform L e n ti G lo b in f o r SC D L e n ti-D C A L D ∞ PLATFORM To discuss

  5. Slide 5: 2020 Silver Lining: De-risked Valley Crossing

    5 2020 Silver Lining: De-risked “Valley Crossing” and Ready to Deliver for Patients Across All Products POC Data “Ted Talk” Deliver to Patients “Valley of Reality” Mature & Lever “Double Down” • Reg Approval • Scale / Globalize • P&R / Bus Model • Educate / Deploy • Mature Pipeline 2010-2017 2018-20

  6. Slide 6: Unlocking Value for Patients and Shareholders

    6 Unlocking Value for Patients and Shareholders bluebird plans to separate into two companies SCD TDT CALD BLUE SGD 2121/7 NextGen MM NHL AML Solids BLUE ONCO • Deliver 3 potentially-curative products to patients • Prove commercial model • Scale, leverage, expand the product platform • Launch ide-ce

  7. Slide 7: Spin out bluebird oncology

    7 Spin out bluebird oncology Create two independent publicly traded companies Anticipated tax–free transaction to close by EOY 2021 With ~$1.3B in cash, intent is for both companies to have sufficient runway at separation Launching Two Independent, Fully Integrated Commercial Stage Companies BLUE SG

  8. Slide 8: Deliver For Patients Now. SGD Snapshot

    8 Deliver For Patients Now. SGD Snapshot

  9. Slide 9: Opportunity to Unlock Value with Increased Focus on Path to Patients

    9 Opportunity to Unlock Value with Increased Focus on Path to Patients & Commercialization SGD Principles FOCUS: Execute near-term catalysts. Filings & launches. DELIVER: Prove commercial model. Novel pricing and reimbursement model for revenues in EU and US. GENERATE: Optimize COGS and reduce costs

  10. Slide 10: Vision to Set the Standard for Successful Gene Therapy Commercialization

    10 2023+ Gene-Therapy Leadership • U.S. SCD launch • Platform scale: Clinical, Commercial, Manufacturing • Geographic and indication expansion • Product optimization (RTC, mobilization) • Next generation research (in-vivo LVV) SCD: • U.S. BLA filing • Launch ready ZYNTEGLO: • U.S. approval and launc

  11. Slide 11: Today's Strategic Foundation

    11 TODAY’S STRATEGIC FOUNDATION… Foundational Building Blocks in Place with a De-risked Business Plan Commercial Infrastructure Regulatory Clarity Durability of Clinical Data Manufacturing Network Pricing and Reimbursement Model Advocacy & Relationships Reduced toxicity conditioning (Forty Seven/GIL

  12. Slide 12: Manufacturing and Commercial Leverage

    12 Manufacturing and Commercial Leverage Meaningful competitive advantages in TDT and SCD: Eligible Patients Anticipated on Label • Significantly longer safety follow up • Significantly longer durability data • Regulatory clarity • Experience with manufacturing scale-up • Commercial infrastructure i

  13. Slide 13: Launch Time. ide-cel Just The Beginning. Oncology Snapshot

    13 Launch Time. ide-cel Just The Beginning. Oncology Snapshot

  14. Slide 14: Oncology Vision: Taking Flight

    14 Oncology Vision: Taking Flight 1 2 3 BUILD & PARTNER: Mobilize cutting edge capabilities to enable launch goals (e.g., manufacturing) 4 CREATE: Optimize product engine to deliver 1-2 INDs per year 5 CRACK the solid tumors code: Deliver differential layered tech portfolio with best of breed partne

  15. Slide 15: Unlocking the Full Potential for Cellular Therapy in Oncology

    15 Clinical & correlative data educating biological hypothesis World-class LVV, mRNA & DP manufacturing capabilities Broad integrated tech & Cellular process development enables designed solutions Unlocking the Full Potential for Cellular Therapy in Oncology Complex problem….. …..demands a multi-par

  16. Slide 16: One-to-Many Strategy: Recoding Traditional R&D

    16 One-to-Many Strategy: Recoding Traditional R&D Nextgen Product Cycling Engine Designed to Rapidly Build, Test, Learn, and Improve PRODUCT CANDIDATES ACADEMIC COLLABORATORS PLATFORM TOOLS & TECH INDUSTRY LEADING PARTNERS 1:Many R&D Strategy RAPID CLINICAL TRANSLATION CAR TCR CCR DARIC ENHANCED COS

  17. Slide 17: Oncology Product Candidates Pipeline

    17 *ide-cel (bb2121) and bb21217 development in collaboration with BMS; MAGE-A4 development in collaboration with Regeneron and Medigene. PRODUCT CANDIDATES PROGRAM AREA PRECLINICAL PHASE 1/2 PHASE 2/3 ide-cel (bb2121)* PRODUCT CANDIDATES PROGRAM AREA PRECLINICAL PHASE 1/2 bb21217* NG MM CAR T PRODU

  18. Slide 18: Our Broad and Deep Approach in Multiple Myeloma

    18 Delivering to Patients: Our Broad and Deep Approach in Multiple Myeloma Nextgen Approaches Focused on Solving Meaningful and Definable Problems to Disrupt MM Care and Ide-cel BMS partnered BLUE owned

  19. Slide 19: bbT369: Multi-layered Enhancements in bNHL

    19 bbT369: Multi-layered Enhancements to Deliver Improved Potency and Patient Outcomes in bNHL Toledo-GCB DLBCL bbT369 CD19CAR Controls bbT369CD19 CAR Product designed to overcome mechanisms thought to limit efficacy of existing CAR T therapies and mediate potent anti-tumor activity with the goal of

  20. Slide 20: CD33 Targeted Regulatable CAR T (DARIC33)

    20 regulated targeting So lu ti o n CD33 Targeted Regulatable CAR T (DARIC33) hematopoietic risk HSC C h a ll e n g e Disease cells similar to & proximal to HSC Problem • Substantial unmet need in AML • Proximity of disease to HSCs = hematopoietic risk • CAR T cell that spares HSCs could transform A

  21. Slide 21: Earlier Product Concept: MAGE-A4 TCR + TGFb Switch Receptor

    21 Earlier Product Concept: Superior MAGE-A4 TCR + TGFb Switch Receptor* Engineered TCR with enhanced potency Product Concept TGFb TGFb Switch Receptor neutralizes TGFb Switch Receptor activates IL12R signaling Validating Data MAGEA4 TCR + Switch Receptor provides tumor control in a human melanoma m

  22. Slide 22: By 2025, the leading oncology cell therapy company

    22 By 2025, the leading oncology cell therapy company • Significant and growing ide-cel revenue • Path to financial sustainability • Strategic optionality BLUE Oncology Vision: An Innovative Cell Therapy R&D Company with First-in-Class BCMA Potential Blockbuster 1 The Cornerstone First Approved BCMA

  23. Slide 23: Time to Run in 2021…

    23 Time to Run in 2021…

  24. Slide 24: Significant Near-term Catalysts Ahead for Each Company

    24 2022 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 Significant Near-term Catalysts Ahead for Each Company beti-cel U.S. BLA submission (mid-year) ide-cel KarMMa studies progressing and evolving ide-cel (bb2121) MM PDUFA, U.S. approval and launch eli-cel U.S. BLA submission (mid-year) LentiGlobin for SCD U.S. BLA

  25. Slide 25: Launching Each Business from a Position of Financial Strength

    25 Financial Overview: Launching Each Business from a Position of Financial Strength JAN 2021 SEPARATION ~EOY 2021 • Strong starting position – $1.3B cash – $0 Debt – Significant R&D cost share support from oncology partners (BMS/Regeneron) – Global rights to SGD products – Emerging commercial produ

  26. Slide 26: Re-shaping bluebird to Deliver over Next Five Years

    26 Re-shaping bluebird to Deliver over Next Five Years MAXIMIZE IMPACT • Deliver deeper therapeutic expertise • Disruption and focus favors patients PATIENTS ENGAGE AND ENABLE • Optimize diverging business needs • Operational simplification & focus • Rejuvenated and committed EMPLOYEES (“birds”) DEL

  27. Slide 27: Simple Vision; Profound Mission

    27 Simple Vision; Profound Mission R AD I C AL C AR E We care in a way that’s intense and truly sets us apart. T H I S I S P E R S O N AL Gene therapy is about saving lives one person at a time. And we are, each of us, personally all in. P I O N E E R S W I T H P U R P O S E We’re exploring new fron

bluebird bio — Conference Presentation (January 2021) on 6ix